These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27281424)

  • 1. The US regulatory and pharmacopeia response to the global heparin contamination crisis.
    Szajek AY; Chess E; Johansen K; Gratzl G; Gray E; Keire D; Linhardt RJ; Liu J; Morris T; Mulloy B; Nasr M; Shriver Z; Torralba P; Viskov C; Williams R; Woodcock J; Workman W; Al-Hakim A
    Nat Biotechnol; 2016 Jun; 34(6):625-30. PubMed ID: 27281424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 4. Dietary supplements quality analysis tools from the United States Pharmacopeia.
    Sarma N; Giancaspro G; Venema J
    Drug Test Anal; 2016; 8(3-4):418-23. PubMed ID: 26857794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 6. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 7. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
    Hyde TD
    Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contaminant in the recalled unfractionated heparin preparations: where is the problem?
    Hoppensteadt DA; Wahi R; Adiguzel C; Iqbal O; Ramacciotti E; Bick RL; Messmore HL; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):261-6. PubMed ID: 18565985
    [No Abstract]   [Full Text] [Related]  

  • 9. USP publishes enforceable chapter on sterile compounding.
    Thompson CA
    Am J Health Syst Pharm; 2003 Sep; 60(18):1814, 1817-8, 1822. PubMed ID: 14521028
    [No Abstract]   [Full Text] [Related]  

  • 10. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 11. Sterile products: advances and challenges in formulation, manufacturing and regulatory aspects--a regulatory review perspective.
    Hussong D
    AAPS PharmSciTech; 2010 Sep; 11(3):1482-4. PubMed ID: 20845091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of currently marketed heparin products: key tests for quality assurance.
    Keire DA; Ye H; Trehy ML; Ye W; Kolinski RE; Westenberger BJ; Buhse LF; Nasr M; Al-Hakim A
    Anal Bioanal Chem; 2011 Jan; 399(2):581-91. PubMed ID: 20680615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensuring global access to quality medicines: role of the US Pharmacopeia.
    ; ; ; Heyman ML; Williams RL
    J Pharm Sci; 2011 Apr; 100(4):1280-7. PubMed ID: 24081465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.
    Hung JC;
    J Nucl Med; 2004 Oct; 45(10):13N, 16N. PubMed ID: 15551509
    [No Abstract]   [Full Text] [Related]  

  • 15. United States Parmacopeia Chapter <797> timeline: 1989 to 2013.
    Newton DW
    Int J Pharm Compd; 2013; 17(4):283-8. PubMed ID: 24261142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the risk-based, phased-in approach for the international harmonization of the regulation of container closure systems for drugs in Taiwan.
    Chang LC; Kang JJ; Gau CS
    Regul Toxicol Pharmacol; 2016 Jun; 77():252-6. PubMed ID: 27016398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy.
    Kastango ES; Bradshaw BD
    Am J Health Syst Pharm; 2004 Sep; 61(18):1928-38. PubMed ID: 15487884
    [No Abstract]   [Full Text] [Related]  

  • 18. Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2.
    Martin M
    Int J Pharm Compd; 2018; 22(6):475-478. PubMed ID: 30384348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP perspectives on particle contamination of injectable products.
    Gallelli JF; Groves MJ
    J Parenter Sci Technol; 1993; 47(6):289-92. PubMed ID: 8120733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential impact of USP 797 and what the JCAAI is doing about it.
    Nathan R
    Allergy Asthma Proc; 2007; 28(2):236-7. PubMed ID: 17479611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.